Modeling the nicotinic receptor loss in dementia using the nicotinic antagonist mecamylamine: Effects on human cognitive functioning
作者:
Paul A. Newhouse,
Alexandra Potter,
June Corwin,
Robert Lenox,
期刊:
Drug Development Research
(WILEY Available online 1994)
卷期:
Volume 31,
issue 1
页码: 71-79
ISSN:0272-4391
年代: 1994
DOI:10.1002/ddr.430310111
出版商: Wiley Subscription Services, Inc., A Wiley Company
关键词: mecamylamine;nicotinic receptors;learning;Alzheimer's disease
数据来源: WILEY
摘要:
AbstractThe loss of central nicotinic receptors is a neurochemical hallmark of several degenerative brain disorders, notably Alzheimer's disease (AD) and Parkinson's disease (PD). However, uncertainty has remained about the significance of this loss for the cognitive symptomatology of these disorders. Symptoms of impaired acquisition of information and short‐term storage, impaired memory consolidation, attention, visual perception, and speed may reflect nicotinic lesions. Administration of the nicotinic antagonist mecamylamine in young and elderly humans produces significant dose‐related impairment of new learning, liberalization of response bias, and slowing of reaction time. These results suggest that mecamylamine may in part model the results of nicotinic receptor loss in AD and that nicotinic augmentation of some aspects of cognitive functioning may be a worthwhile strategy to pursue, particularly if agents can be developed that are more selective than nicotine itself. © 1994 Wiley‐Lis
点击下载:
PDF
(881KB)
返 回